Polymyxin B (sulfate): High-Purity Polypeptide Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate), available as APExBIO product C3090, is a crystalline polypeptide antibiotic mixture composed primarily of polymyxins B1 and B2, derived from Bacillus polymyxa strains. It exerts potent bactericidal activity against major multidrug-resistant Gram-negative bacteria, notably Pseudomonas aeruginosa, by disrupting bacterial cell membranes (APExBIO, product page). In vitro, polymyxin B induces maturation of human dendritic cells, upregulating critical surface markers and activating ERK1/2 and NF-κB signaling pathways. In vivo, dose-dependent improvements in survival and rapid reductions in bacterial load have been demonstrated in murine bacteremia models (polymyxin B sulfate overview, Banorl24). Despite its effectiveness, clinical use is constrained by nephrotoxicity and neurotoxicity risks, underlining the importance of defined, high-purity research reagents.

Biological Rationale

Polymyxin B (sulfate) targets Gram-negative bacteria by exploiting unique features of their outer membrane, specifically the presence of lipopolysaccharides (LPS). Multidrug-resistant Gram-negative organisms, including P. aeruginosa, Acinetobacter baumannii, and certain Enterobacteriaceae, often evade standard antibiotics. Polymyxin B is reserved for cases where other therapies have failed or resistance is anticipated (APExBIO). Its unique cationic polypeptide structure enables binding to the negatively charged LPS, leading to loss of membrane integrity. This mechanism underpins both its bactericidal effect and, in immunology research, its capacity to modulate host-pathogen interactions by neutralizing LPS and influencing antigen-presenting cell activation (VX-661.com). This article extends previous reviews by integrating recent evidence on immunomodulatory roles of polymyxin B beyond direct antibacterial activity.

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B (sulfate) acts as a cationic detergent. The molecule binds to LPS in the outer membrane of Gram-negative bacteria via electrostatic interactions. This displaces divalent cations (Ca²⁺, Mg²⁺) that stabilize the membrane. Membrane permeability increases, resulting in leakage of intracellular components and cell death (APExBIO). In immune cell assays, polymyxin B upregulates co-stimulatory molecules (CD86, HLA class I/II) and activates intracellular signaling, including ERK1/2 and IκB-α/NF-κB pathways. Its molecular weight is 1301.6 g/mol, with a chemical formula of C₅₆H₉₈N₁₆O₁₃·H₂SO₄. The compound is soluble up to 2 mg/mL in PBS (pH 7.2) and is recommended for storage at -20°C for maximal stability (30 days for solutions) (APExBIO).

Evidence & Benchmarks

• Polymyxin B (sulfate) demonstrates potent bactericidal activity against multidrug-resistant Pseudomonas aeruginosa and other Gram-negative bacteria in vitro and in vivo (APExBIO).
• In bacteremia mouse models, administration of polymyxin B improves survival in a dose-dependent manner and reduces bacterial burden rapidly post-infection (see overview at Banorl24).
• In dendritic cell maturation assays, polymyxin B upregulates CD86 and HLA class I/II, and activates ERK1/2 and IκB-α/NF-κB pathways (VX-661.com).
• Purity of APExBIO's Polymyxin B (sulfate) is validated at ≥95%, supporting reproducibility in experimental models (APExBIO).
• Nephrotoxicity and neurotoxicity are the primary dose-limiting toxicities in clinical settings (bioRxiv preprint).

Applications, Limits & Misconceptions

Applications: Polymyxin B (sulfate) is a reference agent in research on multidrug-resistant Gram-negative bacterial infections, particularly in bloodstream, meninges, and urinary tract infection models. It is essential in immunology labs for dendritic cell maturation and LPS neutralization studies. Its use also extends to translational models of sepsis and bacteremia, enabling evaluation of host–bacteria interactions (IFG-1.com). This article clarifies and updates protocol-specific considerations compared with prior reviews.

Common Pitfalls or Misconceptions

• Not effective against Gram-positive bacteria or fungi in standard concentrations: While some minor activity is reported, its primary use is against Gram-negative bacteria (APExBIO).
• Does not reverse established resistance mechanisms: Bacteria with modified LPS or efflux pumps may display intrinsic resistance.
• Toxicity risk is significant in vivo: Nephrotoxicity and neurotoxicity are dose-limiting and require careful dosing (bioRxiv).
• Short-term solution stability: Polymyxin B solutions are stable only for short durations (≤1 month at -20°C), requiring fresh preparations for reproducible results.
• Not suitable as a broad-spectrum antibiotic: Ineffective against most Gram-positive and anaerobic pathogens.

Workflow Integration & Parameters

For experimental applications, dissolve Polymyxin B (sulfate) in PBS (pH 7.2) to a maximal concentration of 2 mg/mL. For cell-based assays, filter-sterilize and avoid repeated freeze-thaw cycles. Use freshly prepared solutions for critical experiments. In dendritic cell assays, typical concentrations range from 1–10 μg/mL. For in vivo murine bacteremia models, dose optimization (e.g., 1–5 mg/kg) is recommended based on infection severity and outcome endpoints (APExBIO). For advanced workflows such as host-microbiome-immune modeling, see Polymyxin B Sulfate: Advanced Tools for Gram-Negative Inf..., which this article extends by providing explicit quantitative preparation and toxicity benchmarks.

Conclusion & Outlook

Polymyxin B (sulfate), as supplied by APExBIO, is a validated, high-purity polypeptide antibiotic for multidrug-resistant Gram-negative bacterial research. Its robust bactericidal and immunomodulatory actions position it as a critical tool for infection and immunology models. Ongoing research seeks to further delineate its immune effects and optimize safety profiles for translational and clinical applications. For technical details and ordering, refer to the APExBIO Polymyxin B (sulfate) product page.